Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Two courses of alefacept evaluated in patients with chronic plaque psoriasis

Jan. 24, 2003

QRX-101 phase II trial in psoriasis cleared to begin

Jan. 24, 2003

Efficacy of TAK-427 in experimental model of atopic dermatitis

Jan. 23, 2003

Positive phase III results for Enbrel in psoriasis

Jan. 21, 2003

Tacrolimus reported safe and effective in chronic actinic dermatitis

Jan. 20, 2003

Shire licenses Solaraze rights in Australia and certain Pacific Rim territories

Jan. 17, 2003

Access licenses amlexanox to Zambon

Jan. 16, 2003

Velac enters phase III development program for acne

Jan. 9, 2003

Proof of concept established in patients for Arachnova's product for dermatitis

Jan. 9, 2003

Finacea approved for topical treatment of rosacea

Jan. 9, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...